CST-107 + CST-2032

CST-107 + CST-2032 is an investigational oral combination therapy developed for the treatment of mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease or Parkinson’s disease. The combination consists of two small molecules: - **CST-2032** is a brain-permeant beta2 adrenoceptor (β2-AR) agonist designed to reactivate adrenergic function in the brain, which is lost early in neurodegenerative diseases. This reactivation targets neurons, microglia, pericytes, and astrocytes to help restore cognitive functions such as memory, attention, executive function, facial recognition, and impulse control. - **CST-107** is nadolol—a brain-sparing beta blocker—co-administered specifically to inhibit peripheral side effects of β2-adrenoceptor agonism (such as increased heart rate), allowing higher dosing for optimal cerebral impact. The unique mechanism aims to improve cognition rapidly and safely by restoring adrenergic signaling pathways critical for maintaining brain health. Phase 1 studies have shown safety and tolerability; Phase 2a trials have demonstrated statistically significant improvements in multiple cognitive domains among patients with MCI or mild dementia from Alzheimer’s or Parkinson’s disease[1][2][3][6][7].

Brand names

CuraXN

Other names

nadolol + CST-2032